Video

Will Biosimilars Reduce Specialty Drug Spending?

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com
Image credit: Dr_Microbe | stock.adobe.com
Image credit: K KStock | stock.adobe.com